Opportunity for REGN Investors to Lead Lawsuit Against Regeneron Pharmaceuticals for Securities Fraud

Class Action Lawsuit Filed Against Regeneron Pharmaceuticals

New York, January 15, 2025
A significant development has unfolded for investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The prominent Rosen Law Firm has initiated a class action lawsuit on behalf of those who purchased Regeneron securities within the specified timeframe between November 2, 2023, and October 30, 2024. This legal action stems from allegations of securities fraud that could affect many investors.

Details of the Allegations

The lawsuit accuses Regeneron of making false and misleading statements during the class period regarding its business practices, particularly relating to its product Eylea. Notably, the lawsuit claims that Regeneron provided financial incentives to distributors, which misleadingly impacted the reported sales figures of Eylea.

Some detailed allegations include:
1. Regeneron is accused of paying credit card fees to distributors with the stipulation that these distributors would not charge additional fees to customers purchasing Eylea with credit cards.
2. These arrangements resulted in a subsidized price structure that favored Eylea, falsely enhancing its sales appeal in the market.
3. The nature of these financial arrangements allegedly misrepresented the sales data reported to federal agencies, potentially violating the False Claims Act.
4. Overall investor confidence was undermined as the truth about these practices came to light, causing significant harm to stock values and investor portfolios.

How to Get Involved

Investors who acquired securities of Regeneron during the class period are encouraged to take action. If you're interested in joining this class action lawsuit, you can either submit your information through the Rosen Law Firm's official website or reach out to Phillip Kim, Esq., who is overseeing the case. The deadline to move for lead plaintiff status is March 10, 2025.

As a lead plaintiff, you would be representative of other class members, guiding the direction of the lawsuit. Moreover, it's important to note that joining this class action is at no cost; investors will not have to pay any fees upfront—this is structured under a contingency arrangement, meaning payment is only required if the case is successful.

Why Choose Rosen Law Firm?

Rosen Law Firm has a distinguished reputation in securities law, having successfully led numerous class action lawsuits. Their expertise includes recovering substantial amounts for investors, demonstrating a proven track record of success. They have been recognized among the top firms in this area, with accolades highlighting their experience and dedication to investor rights.

Choosing counsel with a strong history of success is crucial, as many firms may lack the resources or experience required for effective representation. Investors are advised to thoroughly evaluate their legal options.

Conclusion

This lawsuit presents an opportunity for impacted investors to potentially recover damages from their investments in Regeneron Pharmaceuticals. It emphasizes the importance of solid legal representation in navigating complex securities laws and the corporate landscape. If you believe you were affected by the misrepresentations concerning Regeneron’s business practices, consider looking into this class action to explore your legal options. Remember, the window for joining this lawsuit is limited, so take action promptly!

For more details, to submit your case, or to consult with the attorneys at Rosen Law Firm, visit their website or contact them directly. Stay informed about any updates surrounding this case via their social media channels or official announcements.